Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 17/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.80 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23477299 | 1.00 | STING1 (1.00) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL21133244 | 0.96 | STING1 (0.93) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL26434822 | 0.96 | STING1 (0.93) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL22434621 | 0.95 | STING1 (0.91) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL22434904 | 0.95 | STING1 (0.91) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL23798874 | 0.94 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL23476743 | 0.94 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL19940027 | 0.94 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL23798625 | 0.94 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL23798627 | 0.94 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040053-B2 | Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200179431-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | STING1 1/4885LMNA 2865/4885GMNN 1172/4885 |
| US-20200179431-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | STING1 1/4885LMNA 2514/4885GMNN 940/4885 |
| US-11040053-B2 | Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling | STING1, IRF3, CGAS | STING1 1/4885LMNA 2383/4885GMNN 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.